Compare FTCI & BYSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FTCI | BYSI |
|---|---|---|
| Founded | 2017 | 2010 |
| Country | United States | United States |
| Employees | 232 | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.9M | 31.4M |
| IPO Year | 2021 | 2016 |
| Metric | FTCI | BYSI |
|---|---|---|
| Price | $1.90 | $0.61 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $10.20 | N/A |
| AVG Volume (30 Days) | ★ 459.3K | 329.3K |
| Earning Date | 11-11-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $99,687,000.00 | N/A |
| Revenue This Year | $33.71 | N/A |
| Revenue Next Year | $51.07 | $49.96 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 110.51 | N/A |
| 52 Week Low | $1.83 | $0.57 |
| 52 Week High | $12.75 | $2.44 |
| Indicator | FTCI | BYSI |
|---|---|---|
| Relative Strength Index (RSI) | 34.47 | 39.50 |
| Support Level | N/A | N/A |
| Resistance Level | $2.78 | $0.80 |
| Average True Range (ATR) | 0.23 | 0.11 |
| MACD | -0.03 | -0.02 |
| Stochastic Oscillator | 7.05 | 5.28 |
FTC Solar Inc is a provider of solar tracker systems, supported by proprietary software and value-added engineering services. The company's Solar tracker systems move solar panels throughout the day to maintain an optimal orientation relative to the sun, thereby increasing the amount of solar energy produced at a solar installation. It focuses on providing differentiated products, software, and services that maximize energy generation. The company has launched a new mounting solution to support the installation and use of U.S.-manufactured thin-film modules by project owners. The only segment the company is engaged in is the Manufacturing and Servicing of Solar tracker systems.
BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It operates in Plinabulin pipeline segment. Its first asset, Plinabulin is a novel brain-penetrant microtubule modulator with dendritic cell maturation and vasculature modulation mechanism, which has the potential to help mitigate acquired resistance from prior immune checkpoint inhibitors (ICI) treatment in cancer patients. It is a Selective Immunomodulating Microtubule-Binding Agent (SIMBA), which may provide multiple therapeutic opportunities.